dibekacin and Necrosis

Biofilms are a major concern for clinicians in the treatment of infectious disease because of their resistance to a wide range of antibiotics. Arbekacin, an aminoglycoside antibiotic, is the drug of choice for the treatment of infection caused by methicillin-resistant Staphylococcus aureus (MRSA). However, it has not yet been defined whether arbekacin tends to penetrate into the biofilm structure induced by MRSA infection. In this study, we treated a biofilm mode of MRSA growth with arbekacin, using a rat air-pouch model. The model has the advantage of permitting frequent sampling of exudates for bacterial counts and antibacterial activity. A clear dose-dependent bactericidal effect was detected in rats treated with arbekacin at concentrations between 0.3 and 10 mg/kg, but 0.1 mg/kg of arbekacin was ineffective against the experimental MRSA infection in rats. Morphological studies using scanning electron microscopy and histochemical staining demonstrated that an effective dosage of arbekacin induced dramatic changes in the biofilm membranous structure as well as in the inflammatory response, resulting in eradication of the biofilm structure and resolution of inflammation.

Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Biofilms; Dibekacin; Disease Models, Animal; Granuloma; Humans; Male; Methicillin Resistance; Microscopy, Electron, Scanning; Necrosis; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome

Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Antineoplastic Agents; Cisplatin; Dibekacin; DNA Damage; DNA Fragmentation; Kidney Tubules; L-Lactate Dehydrogenase; LLC-PK1 Cells; Necrosis; Swine; Vancomycin